Like other inhaled prostaglandins, YUTREPIA may cause acute bronchospasm. Patients with asthma or chronic obstructive pulmonary disease (COPD), or other bronchial hyperreactivity, are at increased ...

Liquidia Corp. saw heightened retail chatter Monday after Bank of America increased its stock price target to $25 from $22 ...

The US Food and Drug Administration (FDA) has approved treprostinil inhalation powder (YUTREPIA), a prostacyclin analog ...

A groundbreaking study has revealed that supplementing vasopressin, a hormone linked to social behavior, may improve social ...

Liquidia Corporation ( NASDAQ: LQDA) said on Friday that the U.S. FDA has approved Yutrepia inhalation powder, a prostacyclin ...

为解决口服甲磺酸卡莫司他（Camo）肺部靶向性差、全身副作用及肠道酶解等问题，研究人员开发可自我给药的长效释放聚乙二醇化纳米脂质体（Camo-pegNLs）。通过乙醇注射法制备的该制剂可直接递药至肺部，体外实验显示其具显著抗病毒效果，为 COVID-19 治疗提供 ...

SHANGHAI, May 16, 2025 /PRNewswire/ -- Nuance Pharma ("Nuance") today announces its top-line Phase 3 ENHANCE-CHINA (NCT05743075) trial results evaluating nebulized ensifentrine for the maintenance ...

Lidocaine seems an effective option for relieving procedural pain. The objective of this study was a systematic review with metanalysis to evaluate the analgesic efficacy of jelly, spray, atomized and ...

Thus far, PH-ILD patients in the ASCENT study have been able to titrate to doses that are 3 times higher than the labeled target dose of nebulized Tyvaso. These patients have also shown positive ...

Liquidia Technologies Inc. (NASDAQ:LQDA) reported a larger net loss for Q1 2025 compared to the previous year, despite a slight increase in revenue. The company’s earnings per share (EPS) fell ...

The nebulized mRNA-LNP candidate has nabbed FDA fast track status and aims to tackle the underlying cause of CF by programming cells in the lungs to produce functional CF transmembrane conductance ...